$0.066
-0.031 (-46.45%)Al cierre
- High
- 0.085
- Open
- 0.065
- VWAP
- 0.07
- Vol
- 266.56M
- Mkt Cap
- 3.12M
- Low
- 0.060
- Amount
- 18.79M
- EV/EBITDA, TTM
- 0.00
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Métricas de valoración
Cronología de eventos
Noticias
9.505-21BenzingaWhy Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
7.505-20SeekingAlphaPetros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development
4.504-29BenzingaUS Stocks Mixed; Coca-Cola Posts Upbeat Earnings
2.003-27TipRanks3 Penny Stocks to Watch Now, 3/27/25
8.503-26BenzingaNasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion
PTPI FAQ — answered by Alphio AI
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.